Close Menu

NCI

The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.

Researchers found that some molecularly defined subsets of patients responded to targeted drugs while others didn't.

The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.

The agency hopes to gain data on the efficacy of BRAF targeted drugs used in sequence, and how physicians implement treatments compared to how the drugs are labelled.

Pages